Several tumor features were linked with a higher chance of pCR: no or low ER levels, low or no progesterone receptor levels, ...

A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused ...

Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo ...

For children with high-risk B-cell acute lymphoblastic leukemia (ALL), replacing part of their intensive chemotherapy with ...

Living with incurable small lymphocytic lymphoma means facing new health challenges and fears while finding a balance between ...

The trial met its primary end point of progression-free survival in patients with an International Prognostic Index (IPI) ...

Ameluz photodynamic therapy is the first light-based treatment the FDA has approved for a skin cancer. Here's who it's for, ...

Katie Parrinello was diagnosed with primary mediastinal B-cell lymphoma at 29, reached remission four days before turning 30 ...

Breast cancer survivor Sue Weldon discusses survivorship gaps, integrative therapies alongside treatment and why caregivers ...

Mechanistically, 18F-FET uptake reflects heightened LAT1/LAT2 amino-acid transport in tumor, typically yielding higher ...

With a traditional nipple-sparing mastectomy, the surgeon typically makes a relatively large incision along the lower part of the breast, sometimes measuring 9 to 10 centimeters. The skin and nipple ...

DeLLphi-305 randomized 563 nonprogressing ES-SCLC patients post induction durvalumab plus platinum/etoposide to durvalumab maintenance with or without tarlatamab, with overall survival as the primary ...